ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences (Nasdaq: RSLS) announced the upcoming issuance of U.S. Patent 12,350,179 by the USPTO on July 8, 2025, covering their intragastric balloon system. The patent specifically protects a swallowable capsule design featuring a self-sealing fill valve and degradable release valve that deflates after three months for natural excretion.
The patent will provide protection until at least January 2031, with potential for extension. CEO Paul F. Hickey highlighted that the company has built a substantial intellectual property portfolio, including over 50 patents specifically for their intragastric balloon technology and a total of over 160 issued and pending patents across various proprietary technologies.
ReShape Lifesciences (Nasdaq: RSLS) ha annunciato la prossima emissione del brevetto statunitense 12.350.179 da parte dell'USPTO, prevista per l'8 luglio 2025, che riguarda il loro sistema di palloncino intragastrico. Il brevetto protegge specificamente un design di capsula ingeribile con una valvola di riempimento auto-sigillante e una valvola di rilascio degradabile che si sgonfia dopo tre mesi per un'espulsione naturale.
Il brevetto garantirà protezione almeno fino a gennaio 2031, con possibilità di proroga. Il CEO Paul F. Hickey ha sottolineato che l'azienda ha sviluppato un consistente portafoglio di proprietà intellettuale, comprendente oltre 50 brevetti dedicati specificamente alla tecnologia del palloncino intragastrico e un totale di oltre 160 brevetti concessi e in attesa in diverse tecnologie proprietarie.
ReShape Lifesciences (Nasdaq: RSLS) anunció la próxima emisión de la patente estadounidense 12,350,179 por parte de la USPTO el 8 de julio de 2025, que cubre su sistema de balón intragástrico. La patente protege especÃficamente un diseño de cápsula ingerible que incluye una válvula de llenado auto-sellante y una válvula de liberación degradable que se desinfla después de tres meses para su excreción natural.
La patente brindará protección al menos hasta enero de 2031, con posibilidad de extensión. El CEO Paul F. Hickey destacó que la compañÃa ha construido un importante portafolio de propiedad intelectual, que incluye más de 50 patentes especÃficamente para su tecnologÃa de balón intragástrico y un total de más de 160 patentes otorgadas y en trámite en diversas tecnologÃas propietarias.
ReShape Lifesciences (나스ë‹�: RSLS)ëŠ� 2025ë…� 7ì›� 8ì� USPTOì—서 ë¯¸êµ íŠ¹í—ˆ 12,350,179호가 발행ë� ì˜ˆì •ìž„ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì� 특허ëŠ� 그들ì� 위내 í’ì„ ì‹œìŠ¤í…œì„ ë³´í˜¸í•˜ë©°, 삼킬 ìˆ� 있는 ìº¡ìŠ ë””ìžì�으로ì„� ìžì²´ ë°€ë´� ì¶©ì „ 밸브와 3개월 í›� ìžì—° ë°°ì¶œì� 위해 ìžë™ìœ¼ë¡œ ë°©ì¶œë˜ëŠ” ë¶„í•´ì„� 밸브ë¥� 특징으로 합니ë‹�.
ì� 특허ëŠ� 최소 2031ë…� 1월까지 보호ë¥� ì œê³µí•˜ë©° 연장 가능성ì� 있습니다. CEO í� F. 히키ëŠ� 회사가 위내 í’ì„ ê¸°ìˆ ì—� 대í•� 50ê°� ì´ìƒì� 특허ë¥� í¬í•¨í•˜ì—¬ 다양í•� ë…ì ê¸°ìˆ ì—� ê±¸ì³ 160ê°� ì´ìƒì� ë“±ë¡ ë°� ì¶œì› ì¤‘ì¸ íŠ¹í—ˆë¥� ë³´ìœ í•� 방대í•� ì§€ì � 재산 í¬íЏí´ë¦¬ì˜¤ë¥¼ 구축했다ê³� 강조했습니다.
ReShape Lifesciences (Nasdaq : RSLS) a annoncé la prochaine délivrance du brevet américain 12 350 179 par l'USPTO le 8 juillet 2025, couvrant leur système de ballon intragastrique. Le brevet protège spécifiquement un design de capsule avalable doté d'une valve de remplissage auto-étanche et d'une valve de libération dégradable qui se dégonfle après trois mois pour une excrétion naturelle.
Le brevet offrira une protection au moins jusqu'en janvier 2031, avec possibilité de prolongation. Le PDG Paul F. Hickey a souligné que l'entreprise a constitué un portefeuille important de propriété intellectuelle, comprenant plus de 50 brevets spécifiquement pour leur technologie de ballon intragastrique et un total de plus de 160 brevets délivrés et en attente couvrant diverses technologies propriétaires.
ReShape Lifesciences (Nasdaq: RSLS) gab die bevorstehende Erteilung des US-Patents 12.350.179 durch das USPTO am 8. Juli 2025 bekannt, das ihr intragastrisches Ballonsystem abdeckt. Das Patent schützt speziell ein schluckbares Kapseldesign mit einem selbstabdichtenden Füllventil und einem abbaubaren Entlüftungsventil, das nach drei Monaten entleert wird und auf natürliche Weise ausgeschieden wird.
Das Patent bietet Schutz bis mindestens Januar 2031 mit der Möglichkeit einer Verlängerung. CEO Paul F. Hickey betonte, dass das Unternehmen ein umfangreiches geistiges Eigentumsportfolio aufgebaut hat, das über 50 Patente speziell für ihre intragastrische Ballontechnologie sowie insgesamt über 160 erteilte und anhängige Patente in verschiedenen proprietären Technologien umfasst.
- New patent strengthens intellectual property protection until at least January 2031
- Company holds over 50 patents specifically for intragastric balloon technology
- Total portfolio includes over 160 issued and pending patents
- None.
Insights
ReShape's new patent strengthens IP protection for swallowable intragastric balloon technology through 2031, enhancing competitive positioning in non-surgical weight loss market.
This patent grant represents a strategic enhancement to ReShape Lifesciences' intellectual property portfolio. The newly issued patent (12,350,179) covers a novel intragastric balloon system with several innovative features: a swallowable capsule delivery mechanism, a self-sealing fill valve, and critically, a degradable release valve designed to deflate approximately three months post-inflation.
The technology's significance lies in its potential to overcome key limitations of traditional intragastric balloons, which typically require endoscopic placement and removal procedures. A swallowable system with programmed deflation and natural excretion could substantially reduce procedural complexity and patient discomfort while maintaining the weight loss benefits of gastric volume reduction.
From a competitive standpoint, this patent strengthens ReShape's position in the $8+ billion global weight loss devices market. With protection extending to at least January 2031 (potentially longer with Patent Term Extension), the company has secured a substantial exclusivity window. The fact that this patent builds upon applications dating back to 2011 demonstrates a sustained R&D investment in this technology platform.
This patent joins ReShape's extensive portfolio of over 160 issued and pending patents, including 50+ specifically related to intragastric balloon technology. Such robust IP protection creates significant barriers to entry for potential competitors and enhances the company's licensing and partnership opportunities within the rapidly growing obesity treatment sector.
Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device
IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled, “Intragastric Device.� The patent, related to the Company’s application 18/241,151 and notice of allowance received in April, covers claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. The patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“This pivotal patent represents a significant milestone, further reinforcing our intellectual property portfolio and providing broad protection for our innovative intragastric balloon system,� stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since our initial patent filing in 2011, we have built a strong foundation, securing more than 50 patents specifically related to our intragastric balloon technology and are well positioned to proactively defend and strengthen our competitive position. Today, ReShape Lifesciences holds an impressive portfolio of over 160 issued and pending patents, spanning a wide range of proprietary technologies and we aim to continue building the protective moat around our product portfolio, innovation pipeline, and commercialization strategy.�
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band® System, Obalon® Gastric Balloon System and the DBSN� system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the Obalon® Gastric Balloon System will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known
and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the promise of the Obalon® Gastric Balloon System and the potential path to commercialization of the technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
[email protected]
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
[email protected]
